Avantor 2026 Q3 Earnings Call - AVANTOR INC

Explicit Guidance:

• FY2026 Organic Revenue Growth: Raised to 0.75% – 1.25%, reflecting Q3 outperformance and higher Q4 assumptions; implies 2.5% – 4.5% organic growth in Q4.
• FY2026 Adjusted EPS: Raised to $0.81 – $0.83 per share.
• FY2026 Free Cash Flow: Raised to $525 – $550 million.
• FY2026 Adjusted Effective Tax Rate: Expected between 22% and 22.5%.
• FY2026 Weighted Average Diluted Share Count: Expected at 679 million shares.
• Balance Sheet Target: Expecting to reduce adjusted net leverage ratio to below 3.0x by year-end 2026 (down from 3.1x at end of Q3).
• FX Impact: Foreign exchange expected to be a 150 basis point headwind to reported revenue in Q4, but contributing ~75 bps to full-year reported growth.

Business-Segment Outlook:

• VWR (Distribution & Services):
  • FY2026 Q4 Outlook: Expected to grow in the mid-single-digits organically, assuming Q3 growth drivers persist despite year-end customer spending variability.
  • Competitive Position: Confidence reinforced by growth acceleration; approximately 50% of Q3 growth attributed to commercial initiatives (large contract renewals, share of wallet growth, small/mid-sized accounts, e-commerce).
  • Digital/AI: Plan to expand the "ISA" (Internal Sales Assistant) AI tool and enhance the cross-reference platform to identify product substitutes for sustainability/cost savings.
• BNP (Bioscience & Medtech Products):
  • FY2026 Q4 Outlook: Expected flat to slightly positive organic growth, impacted by a ~400 basis point headwind from discrete customer ordering/shipping comparisons (specifically electronic materials).
  • Long-term Growth: Confident BNP is well-positioned to grow in 2027 and beyond following sequential operational improvements.
  • Product Performance: Process Chemicals grew high single digits; NuSeil grew at a low-teens rate; new orders for NuSeil are strong (renewed contract through 2031 with key customer).
  • Capacity & Operations: Manufacturing throughput increased sequentially in 2026; digital manufacturing workflows (electronic batch records) implemented at two key sites to improve quality and delivery.

Market and Competitive Outlook:

• End Markets: Recovery broadening from large pharma/biotech (Q2) to include higher education and early-stage biotech in North America. Demand viewed as the most constructive in several years.
• Geographic Performance:
  • Americas: Performing very well.
  • Asia: Good activity; region remains smaller for the company.
  • Europe: Lagging due to challenging macro conditions (high energy costs, government funding pressure); guide assumes a static environment, with any recovery serving as a tailwind.
• Industry Trends: AI viewed as a tailwind for productivity in pharma R&D/manufacturing, increasing demand for research and development services across both VWR and BNP.
• Pricing: Pricing contributions for FY2026 estimated at 1% to 2%, lagging slightly behind inflation but improving year-over-year execution compared to 2025.

Macro / Industry Outlook:

• Inflation: Managing mixed inflationary pressures; pricing strategy aimed at offsetting inflation, with improved pass-through mechanisms compared to the prior year.
• Macro Headwinds: Europe faces tighter budgets in academia and government; Middle East conflict impacting inflation inputs.
• Funding Environment: Positive funding environment in North America translating to greater research activity for some customers.

Strategic Initiatives:

• "Revival" Program: Comprehensive turnaround strategy currently in its second year (launched ~1 year ago); focused on simplifying, reinvesting, and growing.
• Leadership: Executive team now complete with the appointment of Todd Garner (CFO) (joined Sept 21) and Mikey Santiago (CIO) (joining next week) from Danaher.
• Investment Priorities: Continuing to invest in AI (digital sales tools, customer experience), supply chain (S&OP, customer service levels), and e-commerce platforms (relaunched vwr.com).
• Investor Day: Scheduled for December 8, to provide a long-term financial framework, deeper segment analysis, and roadmap for value creation.
• Supply Chain Strategy: Finalizing long-term manufacturing strategy (10-year horizon) to place production closer to customers (Asia, Europe, US) for sustainability and security of supply.

Risks and Headwinds to Outlook:

• FX Volatility: Expected 150 bps headwind in Q4.
• Discrete Ordering Patterns: Timing of large customer orders/shipping (noted as a 150 bps headwind in Q3 and 400 bps in Q4 for BNP) can obscure underlying growth trends.
• Inflationary Pressures: Mixed inflation and specific cost increases from the Middle East conflict continue to pressure margins.
• Geographic Divergence: Europe's slower recovery could limit growth if macro conditions do not improve.
• Execution Risk: Continued success depends on the sustained execution of the Revival program and the ability to convert operational improvements into predictable financial results.

Management Tone on the Future:

• Confidence Level: High confidence in the return to sustainable growth; described Q3 as a "milestone" and "tangible evidence" of Revival's success.
• Momentum: Described as "building" and "broadening"; believes demand environment is most constructive in years.
• Hedges: Management is "not done" with Revival; emphasizes that Q3/Q4 progress is just the "beginning" of a long-term transformation to reach historical margin ranges (VWR target 12-13% mentioned as a long-term question, deferred to Investor Day).
• Strategic Focus: Emphasizes "self-funding" through efficiency and operating leverage to drive profitable growth.

Miscellaneous:

• Dividend/Buyback: No specific updates on dividends or buybacks mentioned; focus remains on free cash flow generation to strengthen the balance sheet and reduce leverage.
• Non-GAAP: Reconciliation available on IR website; focus on adjusted EBITDA, adjusted EPS, and adjusted net leverage.